JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

517.58 -2.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

516.11

Max

528.58

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+25.8% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.5B 12B
Vorige openingsprijs	519.66
Vorige sluitingsprijs	517.58

Nieuwssentiment

By Acuity

18%

82%

39 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2026, 00:00 UTC

Winsten

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 apr 2026, 00:00 UTC

Winsten

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 apr 2026, 23:47 UTC

Marktinformatie

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 apr 2026, 23:13 UTC

Acquisities, Fusies, Overnames

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 apr 2026, 22:33 UTC

Winsten

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 apr 2026, 22:17 UTC

Winsten

PLS Executed Offtake Agreement With Ronbay

23 apr 2026, 22:17 UTC

Winsten

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 apr 2026, 22:16 UTC

Winsten

PLS Commences Commissioning of Midstream Demonstration Plant

23 apr 2026, 22:15 UTC

Winsten

PLS Group Reaffirms FY26 Guidance for All Metrics

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 apr 2026, 22:13 UTC

Winsten

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 apr 2026, 22:12 UTC

Winsten

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:12 UTC

Winsten

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:11 UTC

Winsten

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 apr 2026, 22:10 UTC

Winsten

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 apr 2026, 22:09 UTC

Winsten

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 apr 2026, 22:08 UTC

Winsten

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 apr 2026, 22:04 UTC

Winsten

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 apr 2026, 21:56 UTC

Marktinformatie

Winsten

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 apr 2026, 21:27 UTC

Winsten

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 apr 2026, 21:25 UTC

Winsten

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 apr 2026, 21:24 UTC

Winsten

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 apr 2026, 21:24 UTC

Winsten

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 apr 2026, 21:21 UTC

Winsten

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 apr 2026, 21:21 UTC

Winsten

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

25.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 665.67 USD 25.8%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

39 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.